Epiomic Epidemiology Series: Primary Carnitine Deficiency Forecast in 19 Major Markets 2018–2028
Black Swan Analysis Epiomic Epidemiology Forecast Report on Primary Carnitine Deficiency in 19 Major Markets
Systemic Primary Carnitine Deficiency (CDSP) is a rare autosomal recessive disorder caused by mutations in the SLC22A5 gene encoding organic cation transporter type 2 (OCTN2) that transports carnitine across cell membranes. To date, more than 160 unique mutations in the SLC22A5 gene have been reported, and the type of mutation affects the severity of symptoms, with some carriers of less severe mutations being asymptomatic.
This report provides the current prevalent population for CDSP across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several features of CDSP patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of CDSP include:
Reason to buy
Systemic Primary Carnitine Deficiency (CDSP) is a rare autosomal recessive disorder caused by mutations in the SLC22A5 gene encoding organic cation transporter type 2 (OCTN2) that transports carnitine across cell membranes. To date, more than 160 unique mutations in the SLC22A5 gene have been reported, and the type of mutation affects the severity of symptoms, with some carriers of less severe mutations being asymptomatic.
This report provides the current prevalent population for CDSP across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several features of CDSP patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of CDSP include:
- Hepatic and cardiac signs and symptoms
- Anaemia
- Proximal muscle weakness
- Developmental delay
- Respiratory distress
Reason to buy
- Ability to quantify patient populations in global CDSP market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of CDSP and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the prevalent population of CDSP patients.
- Identification of CDSP patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of CDSP patients.
INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR PRIMARY CARNITINE DEFICIENCY
FEATURES OF PRIMARY CARNITINE DEFICIENCY PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR PRIMARY CARNITINE DEFICIENCY
FEATURES OF PRIMARY CARNITINE DEFICIENCY PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX
LIST OF TABLES AND FIGURES
Table 1. Prevalence of primary carnitine deficiency, total (000s)
Table 2. Prevalence of primary carnitine deficiency, males (000s)
Table 3. Prevalence of primary carnitine deficiency, females (000s)
Table 4. Patients with primary carnitine deficiency by presence of clinical symptoms, total (000s)
Table 5. Patients with primary carnitine deficiency by phenotype, total (000s)
Table 6. Primary carnitine deficiency patients with cardiomyopathy, total (000s)
Table 7. Primary carnitine deficiency patients with hyperammonaemia, total (000s)
Table 8. Primary carnitine deficiency patients with hypoglycaemia, total (000s)
Table 9. Primary carnitine deficiency patients with metabolic acidosis, total (000s)
Table 10. Primary carnitine deficiency patients with Reye-like syndrome, total (000s)
Table 11. Primary carnitine deficiency patients with less energetic behaviour, total (000s)
Table 12. Abbreviations and acronyms used in the report
Table 13. USA prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 14. USA prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 15. Canada prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 16. Canada prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 17. France prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 18. France prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 19. Germany prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 20. Germany prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 21. Italy prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 22. Italy prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 23. Spain prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 24. Spain prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 25. UK prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 26. UK prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 27. Poland prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 28. Poland prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 29. Netherlands prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 30. Netherlands prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 31. Russia prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 32. Russia prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 33. Turkey prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 34. Turkey prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 35. Japan prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 36. Japan prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 37. China prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 38. China prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 39. South Korea prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 40. South Korea prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 41. India prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 42. India prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 43. Australia prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 44. Australia prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 45. Brazil prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 46. Brazil prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 47. Mexico prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 48. Mexico prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 49. Argentina prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 50. Argentina prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 1. Prevalence of primary carnitine deficiency, total (000s)
Table 2. Prevalence of primary carnitine deficiency, males (000s)
Table 3. Prevalence of primary carnitine deficiency, females (000s)
Table 4. Patients with primary carnitine deficiency by presence of clinical symptoms, total (000s)
Table 5. Patients with primary carnitine deficiency by phenotype, total (000s)
Table 6. Primary carnitine deficiency patients with cardiomyopathy, total (000s)
Table 7. Primary carnitine deficiency patients with hyperammonaemia, total (000s)
Table 8. Primary carnitine deficiency patients with hypoglycaemia, total (000s)
Table 9. Primary carnitine deficiency patients with metabolic acidosis, total (000s)
Table 10. Primary carnitine deficiency patients with Reye-like syndrome, total (000s)
Table 11. Primary carnitine deficiency patients with less energetic behaviour, total (000s)
Table 12. Abbreviations and acronyms used in the report
Table 13. USA prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 14. USA prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 15. Canada prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 16. Canada prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 17. France prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 18. France prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 19. Germany prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 20. Germany prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 21. Italy prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 22. Italy prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 23. Spain prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 24. Spain prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 25. UK prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 26. UK prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 27. Poland prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 28. Poland prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 29. Netherlands prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 30. Netherlands prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 31. Russia prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 32. Russia prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 33. Turkey prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 34. Turkey prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 35. Japan prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 36. Japan prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 37. China prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 38. China prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 39. South Korea prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 40. South Korea prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 41. India prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 42. India prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 43. Australia prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 44. Australia prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 45. Brazil prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 46. Brazil prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 47. Mexico prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 48. Mexico prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)
Table 49. Argentina prevalence of primary carnitine deficiency by 5-yr age cohort, males (000s)
Table 50. Argentina prevalence of primary carnitine deficiency by 5-yr age cohort, females (000s)